Knut Eis

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

R.C. Hillig, Brice Sautier, Jens Schroeder et al. · Proceedings of the National Academy of Sciences · 2019 · 363 citations · Full text

Use of the Novel Plk1 Inhibitor ZK-Thiazolidinone to Elucidate Functions of Plk1 in Early and Late Stages of Mitosis

Anna Santamaría, Rüdiger Neef, Uwe Eberspächer et al. · Molecular Biology of the Cell · 2007 · 198 citations

Mitophagy, Cell Death, Molecular Biology +20

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

Ulrich Lücking, Arne Scholz, Philip Lienau et al. · ChemMedChem · 2017 · 176 citations · Full text

A Modular Approach to Structurally Diverse Bidentate Chelate Ligands for Transition Metal Catalysis

Remo Kranich, Knut Eis, Oliver Geis et al. · Chemistry - A European Journal · 2000 · 84 citations

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models

Ulrich Lücking, Lars Wortmann, Antje M. Wengner et al. · Journal of Medicinal Chemistry · 2020 · 68 citations · Full text